Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06040567
Other study ID # H-23032160
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 23, 2023
Est. completion date December 31, 2026

Study information

Verified date November 2023
Source Rigshospitalet, Denmark
Contact Britt S Pedersen
Phone +4535458401
Email britt.staevnsbo.pedersen.01@regionh.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The project aims to investigate the validity, and reliability of outcome measures of muscle strength, functioning (gait, balance, and fine motor skills), physical activity, and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy. Further, the project aims to compare physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy with physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills) and daily living in healthy adults.


Description:

In four phases the investigators will evaluate physical activity and the validity, reliability, and responsiveness of the outcome measures in patients with polyneuropathy. During the four phases clinical outcome measures, patient-reported outcomes measures, and accelerometer data on physical activity will be evaluated. The investigators plan to include 400 adult patients with polyneuropathy (acquired, hereditary, and idiopathic) from our clinic and 120 adult healthy controls. The 400 patients with polyneuropathy include the following subtypes of polyneuropathy: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), vasculitis polyneuropathy, Polyneuropathy-Organomegaly-Endocrinopathy-Monoclonal protein-Skin changes (POEMS syndrome), Multifocal Motor Neuropathy (MMN), Charcot Marie Tooth (CMT), hATTR amyloidosis, Diabetic Polyneuropathy (DPN), and idiopathic neuropathy.


Recruitment information / eligibility

Status Recruiting
Enrollment 520
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: Inclusion Criteria patients: > 18 years Diagnosed with polyneuropathy (verified by nerve conduction) Inclusion Criteria healthy controls: > 18 years Healthy Exclusion Criteria: Exclusion Criteria patients: Not verified polyneuropathy Exclusion Criteria healthy controls: Diabetes, brain-, nerve-, muscle-, kidney-, or liver disease. Diagnosed with polyneuropathy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Validity and reliability of outcome measures in polyneuropathy
Patients will be tested, answer patient reported outcome measures, and wear accelerometer at baseline after 2-4 weeks and after 1-2 years.
Healthy controls
Healthy controls will be tested, answer patient reported outcome measures, and wear accelerometer at baseline visit. There is no follow-up in the healthy control group.

Locations

Country Name City State
Denmark Copenhagen Neuromuscular Center, Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary 10-meter Walk Test The patient is asked to 10 meter as fast as possible At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary Six Spot Step Test The patient is instructed to walk 5 meters as fast as possible, while kicking five cylinder blocks out of five circles marked on the floor. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary 6-minute Walk Test The patient will be asked to walk back and forth along a 25 meter walkway for six minutes. They will be instructed to walk as far as possible for six minutes. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary 30 seconds Chair Stand Test The patients will be asked to stand up and sit down as many times as possible in 30 secs with their arms across their chest At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary Dynamic Gait Index The patient will be asked to walk while performing different tasks (walking: normally, while changing speed, while turning head (vertical and horizontal), while turning around, while stepping over obstacles, and walking stairs). At baseline, after 2-4 weeks, and after 1-2 years
Primary Nine Hole Peg Test Fine motor skills At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary Jamar Hand-grip dynamometer (hand-grip-strength) Best of three values At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary Isometric strength measured with hand-held dynamometer Will be tested bilateral at ankle, knee, wrist and elbow At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary Isokinetic muscle strength measured with Biodex System 3 or 4 PRO, Biodex Medical Systems Will be tested bilateral at ankle and knee At baseline (study entry), after 2-4 weeks, and after 1-2 years
Primary SENS motion activity sensor (accelerometer) The SENS motion activity sensor is a wearable accelerometer. It measures physical activity by collecting raw data of accelerations. Data on active time, sedentary time, time spent walking and number of steps taken will be collected.
The sensor will be attached and worn 24/7 (the sensor will be worn the week following baseline tests, and the week after tests at visit three (1-2 years after baseline).
At baseline (study entry), and after 1-2 years
Primary Inflammatory Neuropathy Cause and Treatment (INCAT) Interview based disability scale INCAT evaluates disability of the upper and lower limb. The total INCAT score ranges from 0-10 (low scores indicating no disability and higher scores indicating higher level of disability). At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Rasch-build Overall Disability Scale for Immune-mediated peripheral neuropathies (I-RODS) I-RODS is a 24-item patient reported outcome measure that measures disability. The raw score ranges from 0-48, with 0 indicating severe disability and higher scores indicating lower levels of disability. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Falls Efficacy Scale-International (FES-I) Assesses limitations related to fear of falling. FES-I is a 16-item patient reported outcome measure that measures fear of falling. The score ranges from 16-64, with higher scores indicating greater fear of falling. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Composite Autonomic Symptom Score (COMPAS-31) Assesses autonomic dysfunction Compass-31 is a patient reported outcome measure that measures autonomic dysfunction. Scores ranges from 0-100, with higher scores indicating more severe symptoms of autonomic dysfunction. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANNS) Assesses neuropathic pain S-LANSS is a patient reported outcome measure for identifying neuropathic pain. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Fatigue Severity Scale (FSS) Assesses fatigue FSS is a 9-item patient reported outcome measure that measures fatigue, and the impact of fatigue on physical activity and daily living. The score ranges from 9-63, with a higher score indicating higher levels of fatigue. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary PittsburghSleep Quality Index PittsburghSleep Quality Index is a patient reported outcome measure that assesses sleep quality. The score ranges from 0-21, with higher scores indicating more affected sleep quality At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Major Depression Inventory (MDI) MDI is a patient reported outcome measure that measures depressive symptoms. The score ranges from 0-50, with higher scores indicating deeper depression. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary International Physical Activity Questionaire (IPAQ) International Physical Activity Questionaire (IPAQ) is a patient reported outcome measure that measures physical activity. At baseline (study entry), after 2-4 weeks, and after 1-2 years
Secondary Physical Activity Scale (PAS2) PAS2 is a 7-item patient reported outcome measure that measures physical activity and sedentary behavior. At baseline (study entry), after 2-4 weeks, and after 1-2 years
See also
  Status Clinical Trial Phase
Completed NCT02423434 - Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
Completed NCT05542901 - Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees N/A
Withdrawn NCT01536236 - Spinal Cord Stimulation for Diabetic Polyneuropathy N/A
Active, not recruiting NCT01175928 - Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy Phase 1/Phase 2
Completed NCT00993070 - Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Phase 2/Phase 3
Completed NCT00539175 - Treatment of Painful Diabetic Neuropathy With Photon Stimulation N/A
Completed NCT00278980 - Effect of C-Peptide on Diabetic Peripheral Neuropathy Phase 2
Completed NCT04593992 - HTEMS Treatment of Diabetic Polyneuropathy N/A
Completed NCT01465620 - Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study Phase 3
Completed NCT01079325 - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Phase 2
Completed NCT00406458 - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Phase 2
Recruiting NCT06072573 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06071975 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT05521737 - Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy N/A
Completed NCT01847937 - Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy N/A
Completed NCT00476931 - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Phase 2
Completed NCT00977483 - Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Phase 3
Completed NCT01006915 - Surgical Decompression for Diabetic Neuropathy in the Foot N/A
Completed NCT00501202 - Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN). Phase 2
Completed NCT00307749 - Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy Phase 2